Scarica l'app Stockscreener
1.58
1.25%
-0.02
Dopo l'orario di chiusura:
1.65
0.07
+4.43%
Precedente Chiudi:
$1.60
Aprire:
$1.62
Volume 24 ore:
673.59K
Relative Volume:
1.26
Capitalizzazione di mercato:
$78.64M
Reddito:
-
Utile/perdita netta:
$-51.50M
Rapporto P/E:
-0.395
EPS:
-4
Flusso di cassa netto:
$-47.10M
1 W Prestazione:
-10.73%
1M Prestazione:
-14.13%
6M Prestazione:
-16.40%
1 anno Prestazione:
-78.68%
Intervallo 1D:
$1.555
$1.645
Intervallo di 1 settimana:
$1.555
$2.04
Portata 52W:
$0.87
$9.25
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Nome
Outlook Therapeutics Inc
Settore
Industria
Telefono
(609) 619-3990
Indirizzo
111 S. WOOD AVENUE, ISELIN, NJ
Confronta OTLK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.58 | 78.64M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-02 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-02-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-27 | Aggiornamento | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-08-30 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-13 | Iniziato | CapitalOne | Overweight |
| 2023-04-03 | Iniziato | Guggenheim | Buy |
| 2023-02-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Iniziato | BTIG Research | Buy |
| 2022-09-13 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2019-05-16 | Iniziato | Oppenheimer | Outperform |
| 2019-04-22 | Iniziato | Ascendiant Capital Markets | Buy |
Mostra tutto
Outlook Therapeutics Inc Borsa (OTLK) Ultime notizie
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event | OTLK Stock News - GuruFocus
Outlook Therapeutics, Inc. to Host Virtual Investor Lunch Break Event on June 25, 2025 - Nasdaq
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event - GlobeNewswire
Outlook Therapeutics CEO Reveals Commercial Strategy and Key Milestones in Exclusive Investor Event - Stock Titan
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Outlook LawsuitOTLK - ACCESS Newswire
Outlook Launches Ophthalmic Bevacizumab In Germany And The UK - insights.citeline.com
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Outlook Therapeutics Requests to Dismiss Class Action Filed by Investors - TradingView
Brookline Capital lowers Outlook Therapeutics stock price target on cash balance By Investing.com - Investing.com South Africa
Brookline Capital lowers Outlook Therapeutics stock price target on cash balance - Investing.com Australia
Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ - GuruFocus
Outlook Therapeutics Announces SMC Recommendation Of LYTENAVA For Treatment Of Wet AMD - MarketScreener
Outlook Therapeutics (OTLK) Gains SMC Approval for LYTENAVA in Scotland | OTLK Stock News - GuruFocus
Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD - The Manila Times
Outlook Therapeutics® Announces SMC Recommendation of - GlobeNewswire
Breakthrough: Scotland NHS Approves First-Ever Licensed Bevacizumab Treatment for Wet AMD Patients - Stock Titan
Jane Street Group LLC Purchases 15,008 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Ascendiant Capital lowers Outlook Therapeutics stock price target to $21 - Investing.com Australia
Ascendiant Capital lowers Outlook Therapeutics stock price target to $21 By Investing.com - Investing.com South Africa
Outlook Therapeutics (OTLK): Analyst Lowers Price Target but Mai - GuruFocus
Outlook Therapeutics (OTLK): Analyst Lowers Price Target but Maintains Buy Rating | OTLK Stock News - GuruFocus
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities - GlobeNewswire Inc.
Northern Trust Corp Sells 7,119 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Outlook Therapeutics launches LYTENAVA in Germany and UK By Investing.com - Investing.com South Africa
Outlook Therapeutics® Announces Commercial Launch of - GlobeNewswire
Outlook Therapeutics Announces Commercial Launch Of Lytenava In Germany And UK For Treatment Of Wet AMD - marketscreener.com
Outlook Therapeutics (OTLK) Launches LYTENAVA in European Markets | OTLK Stock News - GuruFocus
Outlook Therapeutics launches LYTENAVA in Germany and UK - Investing.com Australia
Outlook Therapeutics Launches LYTENAVA For Patients With Wet AMD In Germany And The UK - Nasdaq
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD - The Manila Times
Q3 EPS Forecast for Outlook Therapeutics Boosted by Analyst - Defense World
Brokers Issue Forecasts for OTLK FY2026 Earnings - Defense World
Metric Analysis: Outlook Therapeutics Inc (OTLK)’s Key Ratios in the Limelight - DWinneX
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives $10.20 Average Target Price from Brokerages - Defense World
Outlook Therapeutics Announces New Stock and Warrant Offering - TipRanks
Outlook Therapeutics (OTLK) Engages BTIG for Exclusive Offering Management | OTLK Stock News - GuruFocus
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering | OTLK Stock News - GuruFocus
Outlook Therapeutics (OTLK) Announces $13M Public Offering - GuruFocus
Outlook Therapeutics Announces Pricing Of $13.0 Million Public Offering - marketscreener.com
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering - GlobeNewswire
Outlook Therapeutics Secures $13M Financing: Key Details of Share Offering and Double Warrant Coverage - Stock Titan
Outlook Therapeutics (OTLK) Launches Public Offering of Stock an - GuruFocus
Outlook Therapeutics Reports Improved Financials Amid Challenges - TipRanks
Outlook Therapeutics Plans Share Offering; Stock Declines After Hours - marketscreener.com
Outlook Therapeutics announces public stock offering - Investing.com Australia
Outlook Therapeutics announces public stock offering By Investing.com - Investing.com Canada
Outlook Therapeutics (OTLK) Launches Public Offering of Stock and Warrants | OTLK Stock News - GuruFocus
Outlook Therapeutics® Announces Proposed Public Offering of Comm - GuruFocus
Outlook Therapeutics Inc Azioni (OTLK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):